摘要
甲状腺癌的发病率逐年上升,虽然大部分甲癌患者在传统疗法的治疗下预后良好,但碘难治性甲癌患者的死亡风险居高不下。近年来,分子靶向化疗药物及放射性核素靶向治疗的应用给碘难治性甲状腺癌患者带来了希望,其中,索拉菲尼、乐伐替尼、凡德他尼和卡博替尼因能显著延长患者的中位无进展生存期而得到了临床的肯定。本文主要综述了目前用于治疗碘难治性甲状腺癌的靶向药物的临床治疗研究进展。
The incidence of thyroid cancer is increasing year by year. Although most patients with thyroid cancer have a good prognosis under the traditional treatment, the risk of death of patients with iodine refractory thyroid cancer is still high. In recent years, the applications of molecular targeted chemotherapy drugs and radionuclide targeted therapy have brought the hope to patients with iodine refractory thyroid cancer, among which, sorafenib, lenvatinib, vandetanib and cabozantinib have been clinically recognized for significantly extending the median progression-free survival of patients. This paper reviews the progress of targeted drugs in the treatment of iodine refractory thyroid cancer.
作者
唐潇伟
施良
卜婷
王峰
TANG Xiaowei;SHI Liang;BU Ting;WANG Feng(Department of Nuclear Medicine,Nanjing First Hospital,Nanjing Medical University,Nanjing 210006,China)
出处
《标记免疫分析与临床》
CAS
2020年第7期1255-1260,共6页
Labeled Immunoassays and Clinical Medicine
基金
江苏省重点研发专项基金(编号:BE2017612)。
关键词
碘难治性甲状腺癌
分子靶向治疗
放射性核素靶向治疗
Radioactive iodine-refractory thyroid cancer
Molecular targeted therapy
Radionuclide targeted therapy
